Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948095 | 1.00 | HDAC8 (0.46) | HDAC8PRCPHDAC1HDAC3HDAC2 | |
| SCHEMBL29763681 | 0.84 | HDAC8 (0.45) | HDAC8PRCPHDAC1HDAC3HDAC2 | |
| SCHEMBL23926162 | 0.84 | HDAC8 (0.45) | HDAC8PRCPHDAC1HDAC3HDAC2 | |
| SCHEMBL24419866 | 0.83 | HDAC8 (0.57) | HDAC8PRCPHDAC1HDAC3HDAC2 | |
| SCHEMBL30286814 | 0.83 | HDAC8 (0.57) | HDAC8PRCPHDAC1HDAC3HDAC2 | |
| SCHEMBL29763657 | 0.83 | TERT (0.47) | HDAC8HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL24419938 | 0.81 | HHAT (0.40) | HHAT | |
| SCHEMBL29763648 | 0.77 | HDAC8 (0.48) | HDAC8PRCPHDAC1HDAC3HDAC2 | |
| SCHEMBL23926172 | 0.77 | HDAC8 (0.48) | HDAC8PRCPHDAC1HDAC3HDAC2 | |
| SCHEMBL14417385 | 0.75 | PRCP (0.70) | HDAC8PRCPHDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135698-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | The Trustees of Indiana University (US) | 2023-02-22 | — | — | EP | disclosed |